 aduro biotech inc adro insider thomas w dubensky sells  shares  bnb daily daily ratings  news for aduro biotech inc complete the form below to receive the latest headlines and analysts recommendationsfor aduro biotech inc with our free daily email newsletter follow bnbdailynews recent posts kames capital plc decreases position in ross stores inc nasdaqrost efrain rivera sells  shares of paychex inc nasdaqpayx stock credit suisse ag decreases stake in imperial oil ltd imo union pacific corporation nyseunp evp cameron a scott sells  shares jp marvel investment advisors llc has  stake in hershey company the nysehsy suntrust banks inc nysesti shares bought by park national corp oh tudor investment corp et al has  stake in discover financial services dfs enbridge inc nyseenb shares bought by jane street group llc ranger international management lp has  stake in lyondellbasell industries nv nyselyb fox run management llc buys  shares of wabco holdings inc wbc clearbridge investments llc has  million stake in eqt corporation eqt regency centers corporation’s nysereg “equal weight” rating reiterated at barclays plc insider selling phibro animal health corporation nasdaqpahc insider sells  shares of stock virtu financial inc virt downgraded by citigroup inc international paper company ip to issue  quarterly dividend bank of the ozarks nasdaqozrk posts quarterly earnings results meets expectations skandinaviska enskilda banken ab publ continues to hold stake in imperial oil ltd imo fastenal company fast announces quarterly dividend of  emcore corporation emkr receives  consensus price target from brokerages kenneth desgarennes sells  shares of zayo group holdings inc zayo stock aduro biotech inc adro insider thomas w dubensky sells  shares posted by david goldstein on jul nd   no comments aduro biotech inc nasdaqadro insider thomas w dubensky sold  shares of the stock in a transaction on thursday july th the shares were sold at an average price of  for a total transaction of  following the sale the insider now directly owns  shares of the company’s stock valued at approximately  the sale was disclosed in a filing with the sec which can be accessed through the sec website shares of aduro biotech inc nasdaq adro opened at  on friday the firm’s day moving average is  and its day moving average is  the company’s market capitalization is  million aduro biotech inc has a year low of  and a year high of  aduro biotech nasdaqadro last announced its quarterly earnings data on tuesday may nd the biotechnology company reported  earnings per share for the quarter topping the zacks’ consensus estimate of  by  aduro biotech had a negative return on equity of  and a negative net margin of  the firm had revenue of  million for the quarter compared to analyst estimates of  million analysts forecast that aduro biotech inc will post  earnings per share for the current fiscal year illegal activity warning this story was originally published by bnb daily and is owned by of bnb daily if you are viewing this story on another domain it was illegally copied and republished in violation of us and international copyright and trademark law the legal version of this story can be accessed at httpswwwbaseballnewsblogcominsidersellingadurobiotechincadroinsidersellsinstockupdatedhtml get aduro biotech inc alerts hedge funds have recently bought and sold shares of the stock wellington management group llp raised its stake in aduro biotech by  in the first quarter wellington management group llp now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares during the period norges bank purchased a new stake in aduro biotech during the fourth quarter valued at  goldman sachs group inc increased its stake in shares of aduro biotech by  in the first quarter goldman sachs group inc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter renaissance technologies llc increased its stake in shares of aduro biotech by  in the first quarter renaissance technologies llc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter finally highbridge capital management llc bought a new stake in shares of aduro biotech during the first quarter valued at about   of the stock is currently owned by institutional investors several research firms have recently commented on adro zacks investment research cut shares of aduro biotech from a “hold” rating to a “strong sell” rating in a research report on tuesday may nd hc wainwright assumed coverage on shares of aduro biotech in a research report on monday may st they set a “buy” rating and a  price target for the company canaccord genuity reissued a “buy” rating and set a  price target on shares of aduro biotech in a research report on wednesday may rd cowen and company assumed coverage on shares of aduro biotech in a research report on tuesday they set an “outperform” rating for the company finally rodman  renshaw assumed coverage on shares of aduro biotech in a research report on monday may st they set a “buy” rating and a  price target for the company eight equities research analysts have rated the stock with a buy rating the company presently has an average rating of “buy” and a consensus price target of  about aduro biotech aduro biotech inc is an immunotherapy company which focuses on the discovery development and commercialization of therapies that manage the treatment of various diseases including cancer the company’s product candidates from its live attenuated doubledeleted ladd listeria monocytogenes stimulator of interferon genes pathway activator and bselect monoclonal antibody platforms are designed to stimulate andor regulate innate and adaptive immune responses either as single agents or in combination with conventional therapies as well as other immunotherapies receive news  ratings for aduro biotech inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for aduro biotech inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website thomas dubensky  aduro biotech inc  zoominfocom adro thomas w dubensky insider trades for aduro biotech inc x tweet share this bulletin get news bulletins by email bulletin amazon tagged with  loss early friday pacing consumerdiscretionary skid » investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close aduro biotech inc nasdaq adro go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus aduro biotech inc market open  real time quotes jul    am adro quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual thomas w dubensky dr thomas w dubensky jr phd is chief scientific officer at aduro biotech inc dr dubensky was previously employed as chief scientific officer by anza therapeutics inc vice presidentresearch by cerus corp chief scientific officer by immune design corp a principal by chiron viagene inc scientific director by chiron corp and vice president by onyx pharmaceuticals inc he received his undergraduate degree from the university of california berkeley and a doctorate degree from the university of colorado health sciences center transactions date shares transaction value     disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr stephen t isaacs chairman president  chief executive officer mr gregory w schafer chief operating officer ms jennifer lew senior vice presidentfinance dr justin skoble vice presidenttechnical operations ms aimee luck murphy vice presidentclinical development  operations dr natalie r sacks chief medical officer dr dirk g brockstedt executive vice presidentresearch  development dr thomas w dubensky chief scientific officer ms liana wu vice presidentcommercial ms susan lehner media contact ms sylvia r wheeler senior vpinvestor relations  corporate affairs ms nancy kaplan vphuman resources  facility operations mr blaine templeman secretary executive vp  general counsel ms michele devries vice presidentregulatory affairs dr stephen a sherwin independent director dr lok chung chan independent director dr francis patrick mccormick independent director ms stephanie monaghan obrien lead independent director mr william mariner greenman independent director mr ross haghighat independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest atreasury to wind down the myra retirement savings program acan christopher nolan’s ‘dunkirk’ crack china’s market athis type of investing could save the world — just don’t expect outperformance too athese tips can help advisers attract — and keep — high net worth clients aa menacing pattern has revealed itself in the stock market ateaching people how to invest is one of the best marketing moves an adviser can make aa case for buying the freakin’ dip with amazon as the mooch might now say aconsumerdiscretionary sector slides as amazon shares drop on results ashares of newspaper publisher mcclatchy are up more than  a cities where you can buy a huge house for  or less ahow advisers can fight the ‘crisis of trust’ in financial services abreakingstock market opens lower as wall street resumes tech selling adestination maternity plummets toward record low after merger deal terminated athis is how congress could craft a bipartisan healthcare bill ameet the ‘hamilton’ actors who fly crosscountry and play up to  roles in the hit show atrump’s time—and political capital—is quickly running out aconsumer discretionary select sector spdr etf falls  as amazoncom sinks  adow jones industrial average opens less than  lower asp  opens down  anasdaq composite index opens down  loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  insider trading  dubensky thomas w  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  dubensky thomas w select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view sale  pm aduro biotech inc adro dubensky thomas wchief scientific officer    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view option award  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view option award  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view option award  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view option award  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm nana aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view exercise  pm na aduro biotech inc adro dubensky thomas wchief scientific officer   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  leadership  aduro biotech pioneering immunotherapy transforming lives leadership stephen t isaacs chairman president and ceo thomas w dubensky jr phd chief scientific officer natalie r sacks md chief medical officer gregory w schafer chief operating officer hans van eenennaam phd chief operational officer aduro biotech europe andrea van elsas phd chief scientific officer aduro biotech europe   dirk g brockstedt phd executive vice president research  development jennifer lew senior vice president finance quoc lenguyen senior vice president chemistry manufacturing and control blaine templeman executive vice president general counsel and secretary sylvia wheeler senior vice president corporate affairs and investor relations   michele devries vice president regulatory affairs celeste ferber vice president associate general counsel nancy kaplan vice president human resources and facility operations anne moon phd vice president project management aimee murphy vice president clinical development and operations justin skoble phd vice president technical operations liana wu vice president commercial stephen t isaacs chairman president and ceo stephen t isaacs has served as our chairman president and chief executive officer since  prior to aduro in  mr isaacs founded cerus corporation a biomedical products company that commercialized the intercept blood systems he served as president and chief executive officer of cerus from  to  prior to cerus mr isaacs founded and served as chief executive officer and president of hri associates and hri research both biotechnology companies focused on research and development he held a nonteaching faculty position in the department of chemistry at the university of california berkeley from  to  mr isaacs has published over  peerreviewed scientific articles and is an inventor on over  issued patents mr isaacs holds a ba degree in biochemistry from university of california berkeley and had graduate training in organic chemistry in the phd program in the department of chemistry at berkeley thomas w dubensky jr phd chief scientific officer thomas w dubensky jr phd has served as our chief scientific officer since september  from  to  dr dubensky served as chief scientific officer of immune design where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms prior to this in  he cofounded and served as chief scientific officer of anza therapeutics a biotechnology company that was spun out from cerus corporation where he had served as vice president of research for the five years prior during this time dr dubensky helped to develop vaccine platforms based on attenuated strains of listeria monocytogenes which serves as the technology basis for aduro’s ladd platform earlier in his career dr dubensky developed vaccine platforms based on alphaviruses adenoviruses retroviruseslentiviruses and plasmid dna at a number of biotechnology companies including viagene chiron corporation and onyx pharmaceuticals dr dubensky has coauthored more than  scientific papers and is an inventor on  issued us patents with multiple pending applications dr dubensky received his ba in bacteriology and immunology from the university of california berkeley and his phd at the university of colorado health sciences center he conducted his postdoctoral fellowship at harvard medical school in the department of pathology natalie r sacks md chief medical officer natalie sacks md has served as our chief medical officer since september  prior to joining aduro dr sacks served as an advisor on development strategy for multiple firms previously she was vice president of clinical development at onyx pharmaceuticals acquired by amgen where she played a key role in the development and approval of kyprolis® an fdaapproved therapy for the treatment of relapsed or refractory multiple myeloma and in business development strategy prior to that she served as vice president of clinical research for exelixis where she directed the development of a portfolio of small molecules with responsibilities ranging from ind filings to latestage development including latestage development of cometriq™ an fdaapproved therapy for the treatment of medullary thyroid cancer earlier in her career dr sacks served as vice president of clinical development at cell genesys a company focused on the development of cancer vaccines and engineered chimeric antigen receptor car t cells prior to her tenure in biotechnology she served in a variety of research and analytical roles at academic institutions and companies including massachusetts general hospital medical college of pennsylvania and icistuart pharmaceuticals in addition to her industry experience dr sacks holds an active faculty appointment at the university of california san francisco where she is an assistant clinical professor of medicine in the division of hematologyoncology she received her md from the university of pennsylvania school of medicine her ms in biostatistics from harvard university school of public health and her ba in mathematics from bryn mawr college gregory w schafer chief operating officer gregory w schafer has served as our chief operating officer since july  prior to joining aduro he served as chief financial officer of jennerex biotherapeutics acquired by sillajen a privately held biotechnology company from june  to july  where he was responsible for finance accounting planning investor relations and treasury functions from april  to january  he served as chief financial officer of onyx pharmaceuticals acquired by amgen where he was responsible for finance accounting risk management and strategic and operational planning earlier in his career mr schafer served as chief financial officer and vice president of finance for intrabiotics pharmaceuticals and cerus corporation prior to entering the field of biotechology he worked as a management consultant for deloitte  touche llp he received his mba from the anderson graduate school of management at the university of california los angeles and a bse in mechanical engineering from the university of pennsylvania hans van eenennaam phd chief operational officer aduro biotech europe hans van eenennaam phd became chief operational officer of aduro biotech europe in november  prior to its acquisition by aduro in  dr van eenennaam served as chief operational officer of bionovion a company he cofounded in  to focus on the development of innovative therapeutic antibodies in the field of immune oncology earlier in his career he held numerous positions of increasing responsibility at organon in oss netherlands and the organon research center in cambridge massachusetts which was acquired by scheringplough corporation in  and later by merck  co he led the discovery and development of therapeutic monoclonal antibodies and small molecule entities in the field of oncology and immunology while at organon dr van eenennaam in cooperation with a team of scientists discovered pembrolizumab keytruda® a humanized therapeutic antibody acquired by merck and approved in  by the us food and drug administration for the treatment of melanoma and subsequently for additional indications including nonsmall cell lung cancer and head and neck cancer in  he and colleagues were honored by the intellectual property owner’s association with the rd annual inventor of the year award he is named as inventor on seven pending and granted patent families including the patents claiming keytruda and author on over  publications dr van eenennaam received his doctorate in autoimmune biochemistry cum laude from radboud university in nijmegen netherlands andrea van elsas phd chief scientific officer aduro biotech europe andrea van elsas became chief scientific officer of aduro biotech europe in november  prior to its acquisition by aduro in  dr andrea van elsas cofounded bionovion and served as chief scientific officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology from  to  he held numerous positions at organon in oss the netherlands and cambridge massachusetts acquired by scheringplough corporation in  and later by merck  co and as the director of tumor immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab as a postdoctoral researcher from  andrea worked at the university of california berkeley studying antibodies blocking ctla for the treatment of cancer and is a coinventor on the original patents that formed the basis for the development of yervoy® ipilimumab the first checkpoint inhibitor approved in  by the us food and drug administration for the treatment of melanoma dirk g brockstedt phd executive vice president research  development dirk g brockstedt phd joined aduro in april  and has served as our senior vice president of research and development since september  prior to joining aduro dr brockstedt held various positions of increasing responsibility in the immunotherapy group at cerus corporation culminating as director of immunology earlier in his career dr brockstedt worked as a scientist at aventis in the immunotherapy and antiangiogenesis group from  until  focused on developing novel anticancer therapies he has coauthored  scientific papers and is a named inventor on five issued patents and several pending applications dr brockstedt holds a diplomamasters of science in microbiology from the university of kiel and earned his phd from the university of kiel and stanford university the latter at which he served as a postdoctoral fellow at the stanford school of medicine in the department of pathology jennifer lew senior vice president finance jennifer lew joined aduro in october  and has served as our senior vice president of finance since january  prior to joining aduro from  to  ms lew held various positions of increasing responsibility at dynavax technologies culminating as vice president of finance and principal accounting officer responsible for all accounting and finance operations earlier in her career ms lew served as assistant controller and director of finance at qrs corporation a publiclyheld technology company and was a member of the audit practice at ernst  young ms lew earned a ba in economicsaccounting and government from claremont mckenna college and is a certified public accountant inactive status quoc lenguyen senior vice president chemistry manufacturing and control quoc lenguyen joined aduro in september  and has served as our senior vice president of chemistry manufacturing and control cmc since september  he brings over  years of experience in biopharmaceutical operations having held positions of increasing responsibility at both large pharmaceutical and startup companies prior to joining aduro mr lenguyen spent seven years at bayer healthcare as the vice president of technical operations before bayer he served at chiron corporation and novartis ag as director of manufacturing operations earlier in his career he served as senior manager of manufacturing operations at biomarin pharmaceutical where he played an integral role in bringing the company’s lead drug candidate from phase  to commercial launch mr lenguyen holds a bs from university of california davis in biochemistry blaine templeman executive vice president general counsel and secretary blaine templeman joined aduro as executive vice president general counsel and secretary in september  he brings over  years of experience counseling biotechnology companies in the development and commercialization of their products prior to joining aduro mr templeman was a corporate and intellectual property partner at arnold  porter llp where he counseled us and international clients on the protection development and commercialization of their products intellectual property portfolios contract manufacturing clinical trials research and outsourcing his transactional experience includes a variety of collaborations licensing transactions mergers and acquisitions asset sales manufacturing and distribution arrangements and copromotion transactions before arnold  porter llp he was a partner at heller ehrman mr templeman holds a jd from new york university and a bs from oral roberts university sylvia wheeler senior vice president corporate affairs and investor relations sylvia wheeler joined aduro as senior vice president corporate affairs and investor relations in january  she brings over  years of experience in the biopharmaceutical industry having served in a number of executive management roles encompassing investor and media relations as well as corporate and product communications prior to joining aduro ms wheeler served as vice president of investor relations and corporate affairs at relypsa after having served this same role for hyperion therapeutics earlier in her career she was vice president corporate communications at affymax where over a sixyearperiod she supported the company’s transition from a research and development company to a commercial organization with its first marketed product ms wheeler held similar communications roles at depomed cerus corporation and coulter pharmaceutical ms wheeler holds an mba from university of san francisco and a ba in biology from san francisco state university michele devries vice president regulatory affairs michele devries joined aduro in  and currently serves as vice president of regulatory affairs she is responsible for all aspects of regulatory strategy implementation and oversight of aduro’s proprietary partnered and licensed programs both in the us and internationally prior to aduro ms devries served as director of regulatory affairs for intarcia therapeutics in this role she managed key regulatory aspects of intarcia’s drug delivery system served as the primary contact for regulatory authorities and was responsible for all aspects of routine and specialized regulatory submissions including preparation for launch of four global phase  studies before intarcia she held escalating regulatory affairs positions at vaxgen intermune and tularik she received her bs in chemical engineering from the university of minnesota celeste ferber vice president associate general counsel celeste ferber joined aduro in  and currently serves as vice president associate general counsel prior to aduro she was with shearman  sterling llp where she served as counsel in the capital markets group ms ferber has over  years of experience advising public and private companies on corporate and finance matters including securities offerings mergers acquisitions and strategic transactions corporate governance and securities law compliance before shearman  sterling ms ferber was counsel at morrison  foerster llp working in their palo alto hong kong and san diego offices ms ferber received her jd from the university of california hastings college of law and her ba in economics from bucknell university she is the author of numerous publications regarding legal matters nancy kaplan vice president human resources and facility operations nancy kaplan joined aduro in  and currently serves as aduro’s vice president of human resources and facility operations prior to aduro ms kaplan worked with a wide variety of small biotech companies applying her broad generalist skill set to establish and bolster finance human resources facility management grant administration and investor relations functions in addition she was marketing communications manager at applied biosystems and supervised biotech accounts at lena chow advertising earlier in her career ms kaplan was part of the founding group at invitron corp a mammalian cell contract manufacturer ms kaplan holds a bs in agronomy from oregon state university anne moon phd vice president project management anne moon phd joined aduro in  and currently serves as vice president of project management prior to aduro dr moon was a founding team member of jennerex biotherapeutics acquired by sillajen where she served as vice president of product development earlier in her career dr moon was part of the startup team at cytokinetics establishing the cellbased screening program and served as project manager of the oncolytic virus program at onyx pharmaceuticals acquired by amgen after completing postdoctoral work within the small molecule therapeutics program targeting small gtpases she received her phd in molecular and cell biology from the university of california berkeley and her ba in biology from harvard university aimee murphy vice president clinical development and operations ms murphy joined aduro in  and currently serves as vice president of clinical development and operations prior to aduro ms murphy advanced the development of the ladd live attenuated doubledeleted immunotherapy platform at both cerus corporation and anza therapeutics where she managed the first phase  studies that led to aduros existing ladd clinical programs prior to focusing on ladd she worked on the development of prophylactic vaccines and drugs for oncology and infectious diseases at vaxgen coulter pharmaceuticals and shaman pharmaceuticals additionally ms murphy brings experience in quality assurance from bayer pharmaceuticals she holds a bs in biology from pepperdine university justin skoble phd vice president technical operations justin skoble phd joined aduro in  and currently serves as aduro’s vice president of technical operations prior to aduro dr skoble held positions with increasing responsibilities in the molecular biology and process development departments at anza therapeutics and cerus corporation he earned his ba in biology from vassar college and his phd in molecular and cell biology from the university of california berkeley in the laboratory of dr daniel portnoy additionally dr skoble performed postdoctoral work at the university of california san francisco ucsf in the laboratory of dr jeff cox professor of microbiology and immunology at ucsf liana wu vice president commercial liana wu joined aduro in april  as vice president commercial bringing with her over  years of commercial experience in the biotechnology industry and a successful track record in brand development and product launches prior to aduro ms wu spent nine years at onyx pharmaceuticals acquired by amgen where she was most recently vice president oncology franchise while at onyx she was instrumental in overseeing the collaboration with bayer for nexavar and stivarga in the united states earlier in her career ms wu held several sales and marketing positions at genentech with responsibilities associated with the company’s key oncology brands including rituxan herceptin and tarceva ms wu holds a master’s in public health from the johns hopkins university and a bs in economics from the wharton school at the university of pennsylvania leadership board of directors scientific advisory board culture global headquarters community affairs home about us leadership board of directors scientific advisory board culture global headquarters community affairs pipeline clinical trials access to our investigational agents technology immunotherapy ladd sting pathway bselect antibodies scientific publications intellectual property partnerships media press releases corporate video investors press releases events  presentations corporate governance leadership board of directors committee composition financials  filings financial reports quarterly results analyst coverage stock information stock chart faqs careers contact home about us leadership board of directors scientific advisory board culture global headquarters community affairs pipeline clinical trials access to our investigational agents technology immunotherapy ladd sting pathway bselect antibodies scientific publications intellectual property partnerships media press releases corporate video investors press releases events  presentations corporate governance leadership board of directors committee composition financials  filings financial reports quarterly results analyst coverage stock information stock chart faqs careers contact privacy policy terms and conditions of use   aduro biotechall rights reserved privacy policy terms and conditions of use website design hane chow inc twitterlinkedin thomas w dubensky jr phd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in thomas w dubensky jr phd chief scientific officer at aduro biotech view full profile are you thomas w dubensky jr phd claim your profile   sign up for equilar atlas and view thomas w dubensky jr phds full profile with equilar atlas you can identify corporate executives in thomas w dubensky jr phds network and community follow changes in thomas w dubensky jr phds employment and moneyinmotion connect with thomas w dubensky jr phd through your network of contacts thomas w dubensky jr phds executive work history current chief scientific officer aduro biotech past to view thomas w dubensky jr phds complete executive work history sign up now age      thomas w dubensky jr phds biography thomas w dubensky jr phd has served as our chief scientific officer since september  from  to  dr dubensky served as chief scientific officer of immune design corp a biotechnology company where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms he was a cofounder and chief scientific officer of anza therapeutics inc a biotechnology company which was spun out from cerus corporation in  where he served as the vice president of research beginning in  at cerus and at anza he helped to develop  read more thomas w dubensky jr phd has served as our chief scientific officer since september  from  to  dr dubensky served as chief scientific officer of immune design corp a biotechnology company where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms he was a cofounder and chief scientific officer of anza therapeutics inc a biotechnology company which was spun out from cerus corporation in  where he served as the vice president of research beginning in  at cerus and at anza he helped to develop vaccine platforms based on attenuated strains of listeria monocytogenes which serve as the technology basis for aduro previously dr dubensky developed vaccine platforms based on alphaviruses adenoviruses retroviruseslentiviruses and plasmid dna in positions of increasing responsibility at viagene biotech inc chiron corporation and onyx pharmaceuticals inc all biotechnology companies dr dubensky has coauthored more than  scientific papers and is an inventor on more than  issued us patents and multiple pending applications dr dubensky received his ba in bacteriology and immunology from the university of california berkeley he earned his phd at the university of colorado health sciences center and he was a postdoctoral fellow at harvard medical school in the department of pathology source aduro biotech on    sign up for equilar atlas and view thomas w dubensky jr phds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like thomas w dubensky jr phd more specifically youll be able to identify corporate executives in thomas w dubensky jr phds network and community follow changes in thomas w dubensky jr phds employment and moneyinmotion connect with thomas w dubensky jr phd through your network of conections view full profile   search for over  executive profiles bio example thomas w dubensky jr phd thomas w dubensky jr phds connections  sign up now to view thomas w dubensky jr phds  connections » frank mccormick former board member aduro biotech gerald chan former board member aduro biotech stephanie m obrien former board member aduro biotech blaine templeman executive vice president secretary and general counsel aduro biotech william m greenman dir president and chief executive officer cerus corporation stephen t isaacs chairman of the board president and chief executive officer aduro biotech ross haghighat board member aduro biotech gregory w schafer chief operating officer aduro biotech stephen a sherwin board member neurocrine biosciences inc natalie sacks chief medical officer aduro biotech popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft ﻿ brokerages set aduro biotech inc nasdaqadro price target at   chaffey breeze daily ratings  news for aduro biotech inc complete the form below to receive the latest headlines and analysts recommendationsfor aduro biotech inc with our free daily email newsletter follow chaffeybreeze recent posts zacks osisko gold royalties ltd or receives consensus recommendation of “strong buy” from brokerages first trust advisors lp has  position in career education corporation ceco safeguard scientifics inc sfe stake maintained by state board of administration of florida retirement system great west life assurance co can has  position in cobiz financial inc nasdaqcobz  earnings per share expected for eros international plc eros this quarter brokerages set schneider national inc sndr price target at  brokerages set aduro biotech inc nasdaqadro price target at  analysts set carolina financial corporation caro price target at  hartford financial services group inc the nysehig receives  consensus pt from analysts synaptics incorporated syna lowered to “sell” at zacks investment research abbott laboratories abt receives new coverage from analysts at guggenheim sequential brands group inc sqbg lifted to “buy” at zacks investment research kier group plc kie upgraded by numis securities ltd to “buy” ssab svenskt ssaay downgraded by zacks investment research wipro limited wit rating increased to hold at zacks investment research ahold nv adrny upgraded to buy by zacks investment research ks ag kpluf stock rating upgraded by societe generale kuehnenagel intl khngy upgraded by zacks investment research to “buy” wns holdings limited wns downgraded to “hold” at zacks investment research infineon technologies ag etrifxa pt set at € by credit suisse group brokerages set aduro biotech inc nasdaqadro price target at  posted by joanna charbonneau on jul th   no comments aduro biotech inc nasdaqadro has been given an average rating of “buy” by the eight analysts that are presently covering the stock marketbeat ratings reports eight investment analysts have rated the stock with a buy rating the average month price target among brokerages that have updated their coverage on the stock in the last year is  a number of research firms have weighed in on adro cowen and company began coverage on shares of aduro biotech in a research note on tuesday they set an “outperform” rating on the stock zacks investment research raised shares of aduro biotech from a “hold” rating to a “buy” rating and set a  price target on the stock in a research note on tuesday july th canaccord genuity set a  price target on shares of aduro biotech and gave the stock a “buy” rating in a research note on monday march th hc wainwright began coverage on shares of aduro biotech in a research note on monday may st they set a “buy” rating and a  price target on the stock finally rodman  renshaw began coverage on shares of aduro biotech in a research note on monday may st they set a “buy” rating and a  price target on the stock get aduro biotech inc alerts copyright violation notice this story was published by chaffey breeze and is the sole property of of chaffey breeze if you are accessing this story on another publication it was copied illegally and reposted in violation of us and international copyright and trademark law the correct version of this story can be accessed at httpswwwchaffeybreezecombrokeragessetadurobiotechincnasdaqadropricetargetathtml in other aduro biotech news insider thomas w dubensky sold  shares of the firm’s stock in a transaction on friday may th the shares were sold at an average price of  for a total transaction of  following the completion of the transaction the insider now directly owns  shares of the company’s stock valued at approximately  the sale was disclosed in a document filed with the sec which is available through this hyperlink also evp dirk g brockstedt sold  shares of the firm’s stock in a transaction on thursday may th the stock was sold at an average price of  for a total transaction of  following the transaction the executive vice president now directly owns  shares of the company’s stock valued at  the disclosure for this sale can be found here insiders have sold a total of  shares of company stock worth  in the last ninety days  of the stock is currently owned by insiders hedge funds and other institutional investors have recently made changes to their positions in the company tudor investment corp et al bought a new position in shares of aduro biotech during the fourth quarter valued at  quantitative systematic strategies llc bought a new position in shares of aduro biotech during the first quarter valued at  daiwa sb investments ltd bought a new position in shares of aduro biotech during the first quarter valued at  creative planning raised its position in shares of aduro biotech by  in the first quarter creative planning now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter finally parametric portfolio associates llc raised its position in shares of aduro biotech by  in the first quarter parametric portfolio associates llc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares in the last quarter  of the stock is owned by institutional investors shares of aduro biotech adro traded up  during midday trading on monday reaching  the company’s stock had a trading volume of  shares the company’s market capitalization is  million the firm’s  day moving average price is  and its day moving average price is  aduro biotech has a year low of  and a year high of  aduro biotech nasdaqadro last posted its quarterly earnings results on tuesday may nd the biotechnology company reported  earnings per share for the quarter topping the zacks’ consensus estimate of  by  the company had revenue of  million for the quarter compared to the consensus estimate of  million aduro biotech had a negative net margin of  and a negative return on equity of  on average analysts predict that aduro biotech will post  eps for the current year about aduro biotech aduro biotech inc is an immunotherapy company which focuses on the discovery development and commercialization of therapies that manage the treatment of various diseases including cancer the company’s product candidates from its live attenuated doubledeleted ladd listeria monocytogenes stimulator of interferon genes pathway activator and bselect monoclonal antibody platforms are designed to stimulate andor regulate innate and adaptive immune responses either as single agents or in combination with conventional therapies as well as other immunotherapies receive news  ratings for aduro biotech inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for aduro biotech inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website publications authored by thomas w dubensky  pubfactscom thomas w dubensky are you thomas w dubensky   register this author register this author earle a chiles research instituteunited states toggle navigation publications publications publications reads of a sting agonist given with ox receptor and pdl modulators primes immunity and reduces tumor growth in tolerized mice authors jeremy b foote marleen kok james m leatherman todd d armstrong bridget c marcinkowski laureen s ojalvo david b kanne elizabeth m jaffee thomas w dubensky leisha a emenscancer immunol res  jun  epub  may department of oncology kimmel cancer center johns hopkins school of medicine baltimore maryland june  download full paper comment on the common rhgarq human tmem is a null allele authors kelsey e sivick natalie h surh anthony l desbien eric p grewal george e katibah sarah m mcwhirter thomas w dubenskyj immunol  junsting program aduro biotech inc berkeley ca june  download full paper new cancer immunotherapy agents in development a report from an associated program of the stannual meeting of the society for immunotherapy of cancer  authors prasad s adusumilli edward cha mark cornfeld thomas davis adi diab thomas w dubensky elizabeth evans jane l grogan bryan a irving rom s leidner shane a olwill patrick soonshiong frederic triebel david tuck adrian bot roger d dansey charles g drake gordon j freeman ramy ibrahim salil patel daniel s chenj immunother cancer   epub  jun genentechroche  dna way south san francisco ca  usajune  download full paper the host sting pathway at the interface of cancer and immunity authors leticia corrales sarah m mcwhirter thomas w dubensky thomas f gajewskij clin invest  jul  epub  jul july  download full paper sting pathway activation stimulates potent immunity against acute myeloid leukemia authors emily curran xiufen chen leticia corrales douglas e kline thomas w dubensky priyanka duttagupta marcin kortylewski justin klinecell rep  jun  epub  jun department of medicine university of chicago chicago il  usa committee on immunology university of chicago chicago il  usa electronic address june  download full paper antagonism of the sting pathway via activation of the aim inflammasome by intracellular dna authors leticia corrales sengryong woo jason b williams sarah m mcwhirter thomas w dubensky thomas f gajewskij immunol  apr  epub  feb department of pathology the university of chicago chicago il  section of hematologyoncology  department of medicine the university of chicago chicago il  april  download full paper systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination authors christopher m jackson christina m kochel christopher j nirschl nicholas m durham jacob ruzevick angela alme brian j francica jimmy elias andrew daniels thomas w dubensky peter lauer dirk g brockstedt emily g baxi peter a calabresi janis m taube carlos a pardo henry brem drew m pardoll michael lim charles g drakeclin cancer res  mar  epub  oct department of oncology johns hopkins university baltimore maryland brady urological institute johns hopkins university baltimore maryland march  download full paper radiotherapy combined with novel stingtargeting oligonucleotides results in regression of established tumors authors jason r baird david friedman benjamin cottam thomas w dubensky david b kanne shelly bambina keith bahjat marka r crittenden michael j goughcancer res  jan  epub  nov earle a chiles research institute robert w franz cancer center providence portland medical center portland oregon january  download full paper direct activation of sting in the tumor microenvironment leads to potent and systemic tumor regression and immunity authors leticia corrales laura hix glickman sarah m mcwhirter david b kanne kelsey e sivick george e katibah sengryong woo edward lemmens tamara banda justin j leong ken metchette thomas w dubensky thomas f gajewskicell rep  may  epub  may department of pathology the university of chicago  eth street gcis h chicago il  usa electronic address may  download full paper sting agonist formulated cancer vaccines can cure established tumors resistant to pd blockade authors juan fu david b kanne meredith leong laura hix glickman sarah m mcwhirter edward lemmens ken mechette justin j leong peter lauer weiqun liu kelsey e sivick qi zeng kevin c soares lei zheng daniel a portnoy joshua j woodward drew m pardoll thomas w dubensky young kimsci transl med  aprradepartment of otolaryngologyhead and neck surgery johns hopkins university school of medicine baltimore md  usa department of oncology and the sidney kimmel comprehensive cancer center johns hopkins university school of medicine baltimore md  usa april  download full paper virological and preclinical characterization of a dendritic cell targeting integrationdeficient lentiviral vector for cancer immunotherapy authors jared m odegard brenna kelleyclarke semih u tareen david j campbell patrick a flynn christopher j nicolai megan m slough chintan d vin patrick j mcgowan lisa t nelson jan ter meulen thomas w dubensky scott h robbinsj immunother  febmarimmune design corp †tria bioscience corp seattle wafebruary  download full paper attenuated listeria monocytogenes vectors overcome suppressive plasma factors during hiv infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus authors elizabeth a miller meredith r spadaccia thomas norton morgan demmler ramya gopal meagan obrien nathaniel landau thomas w dubensky peter lauer dirk g brockstedt nina bhardwajaids res hum retroviruses  jan division of infectious diseases icahn school of medicine at mount sinai  new york new yorkjanuary  download full paper a listeria vaccine and depletion of tregulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice authors bridget p keenan yvonne saenger michel i kafrouni ashley leubner peter lauer anirban maitra agnieszka a rucki andrew j gunderson lisa m coussens dirk g brockstedt thomas w dubensky raffit hassan todd d armstrong elizabeth m jaffeegastroenterology  jun e epub  mar the sidney kimmel comprehensive cancer center the skip viragh center for clinical pancreatic cancer research and the sol goldman pancreatic cancer center at johns hopkins baltimore maryland electronic address june  download full paper design of a novel integrationdeficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells authors semih u tareen brenna kelleyclarke christopher j nicolai linda a cassiano lisa t nelson megan m slough chintan d vin jared m odegard derek d sloan neal van hoeven james m allen thomas w dubensky scott h robbinsmol ther  mar  epub  dec  immune design corp seattle washington usa  tria bioscience corp seattle washington usamarch  download full paper rationale progress and development of vaccines utilizing stingactivating cyclic dinucleotide adjuvants authors thomas w dubensky david b kanne meredith l leongther adv vaccines  novaduro biotech inc berkeley ca usanovember  download full paper killed but metabolically active vaccines authors thomas w dubensky justin skoble peter lauer dirk g brockstedtcurr opin biotechnol  dec  epub  may aduro biotech inc berkeley ca  united states december  download full paper a liveattenuated listeria vaccine anz and a liveattenuated listeria vaccine expressing mesothelin crs for advanced cancers phase i studies of safety and immune induction authors dung t le dirk g brockstedt ran nirpaz johannes hampl shruti mathur john nemunaitis daniel h sterman raffit hassan eric lutz bentley moyer martin giedlin janalynn louis elizabeth a sugar alice pons andrea l cox jordana levine aimee luck murphy peter illei thomas w dubensky joseph e eiden elizabeth m jaffee daniel a laheruclin cancer res  feb  epub  dec the sidney kimmel cancer center johns hopkins baltimore maryland  usa february  download full paper adjuvants for cancer vaccines authors thomas w dubensky steven g reedsemin immunol  jun  epub  may immune design corporation  columbia st ste  seattle wa  united statesjune  download full paper priming and activation of human ovarian and breast cancerspecific cd t cells by polyvalent listeria monocytogenesbased vaccines authors gomathinayagam sinnathamby peter lauer jennifer zerfass bill hanson aykan karabudak jonathan krakover angeles alvarez secord timothy m clay michael a morse thomas w dubensky dirk g brockstedt ramila philip martin giedlinj immunother  octimmunotope inc the pennsylvania biotechnology center doylestown pa  usaoctober  download full paper impact of preexisting vectorspecific immunity on vaccine potency characterization of listeria monocytogenesspecific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice authors meredith l leong johannes hampl weiqun liu shruti mathur keith s bahjat william luckett thomas w dubensky dirk g brockstedtinfect immun  sep  epub  jun anza therapeutics concord california usa september  download full paper suppression of cellmediated immunity following recognition of phagosomeconfined bacteria authors keith s bahjat nicole meyermorse edward e lemmens jessica a shugart thomas w dubensky dirk g brockstedt daniel a portnoyplos pathog  sep e epub  sep earle a chiles research institute robert w franz cancer research center providence cancer center portland oregon united states of america september  download full paper killed but metabolically active bacillus anthracis vaccines induce broad and protective immunity against anthrax authors justin skoble john w beaber yi gao julie a lovchik laurie e sower weiqun liu william luckett johnny w peterson richard calendar daniel a portnoy c rick lyons thomas w dubenskyinfect immun  apr  epub  jan anza therapeutics incorporated concord california  usa april  download full paper kbma listeria monocytogenes is an effective vector for dcmediated induction of antitumor immunity authors mojca skoberne alice yewdall keith s bahjat emmanuelle godefroy peter lauer edward lemmens weiqun liu will luckett meredith leong thomas w dubensky dirk g brockstedt nina bhardwajj clin invest  dec  epub  nov cancer institute new york university school of medicine new york new york  usa december  download full paper promises and challenges for the development of listeria monocytogenesbased immunotherapies authors dirk g brockstedt thomas w dubenskyexpert rev vaccines  sepanza therapeutics inc  stanwell drive concord ca  usa september  download full paper constitutive activation of the prfa regulon enhances the potency of vaccines based on liveattenuated and killed but metabolically active listeria monocytogenes strains authors peter lauer bill hanson edward e lemmens weiqun liu william s luckett meredith l leong heather e allen justin skoble keith s bahjat nancy e freitag dirk g brockstedt thomas w dubenskyinfect immun  aug  epub  jun anza therapeutics inc concord ca  usa august  download full paper listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity authors gregory t crimmins anat a herskovits kai rehder kelsey e sivick peter lauer thomas w dubensky daniel a portnoyproc natl acad sci u s a  jul  epub  jul department of molecular and cell biology university of california berkeley ca  usajuly  download full paper activation of immature hepatic nk cells as immunotherapy for liver metastatic disease authors keith s bahjat rodney a prell heather e allen weiqun liu edward e lemmens meredith l leong daniel a portnoy thomas w dubensky dirk g brockstedt martin a giedlinj immunol  deccerus corporation concord ca  usa december  download full paper role of pd and its ligand bh in early fate decisions of cd t cells authors monica v goldberg charles h maris edward l hipkiss andrew s flies lijie zhen rubin m tuder joseph f grosso timothy j harris derese getnet katharine a whartenby dirk g brockstedt thomas w dubensky lieping chen drew m pardoll charles g drakeblood  jul  epub  mar department of oncology johns hopkins sidney kimmel comprehensive cancer center baltimore md  usajuly  download full paper inactivation of parvovirus b in human platelet concentrates by treatment with amotosalen and ultraviolet a illumination authors lynette sawyer deborah hanson grace castro william luckett thomas w dubensky adonis stassinopoulostransfusion  juncerus corporation concord california  usa june  download full paper cytosolic entry controls cdtcell potency during bacterial infection authors keith s bahjat weiqun liu edward e lemmens stephen p schoenberger daniel a portnoy thomas w dubensky dirk g brockstedtinfect immun  nov  epub  sep cerus corporation  stanwell drive concord ca  usa november  download full paper interferonproducing killer dendritic cells provide a link between innate and adaptive immunity authors camie w chan emily crafton hongni fan james flook kiyoshi yoshimura mario skarica dirk brockstedt thomas w dubensky monique f stins lewis l lanier drew m pardoll franck housseaunat med  feb  epub  jan sidney kimmel comprehensive cancer center johns hopkins university school of medicine crb  orleans street baltimore maryland  usafebruary  download full paper selective targeting of antitumor immune responses with engineered liveattenuated listeria monocytogenes authors kiyoshi yoshimura ajay jain heather e allen lindsay s laird christina y chia sowmya ravi dirk g brockstedt martin a giedlin keith s bahjat meredith l leong jill e slansky david n cook thomas w dubensky drew m pardoll richard d schulickcancer res  janimmunology and hematopoiesis division department of medical oncology sidney kimmel cancer center johns hopkins medical institutions  orleans street baltimore md  usajanuary  download full paper listeriabased cancer vaccines that segregate immunogenicity from toxicity authors dirk g brockstedt martin a giedlin meredith l leong keith s bahjat yi gao william luckett weiqun liu david n cook daniel a portnoy thomas w dubenskyproc natl acad sci u s a  sep  epub  sep cerus concord ca  usa september  download full paper listeria monocytogenes as a vaccine vector virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy authors holly starks kevin w bruhn hao shen ronald a barry thomas w dubensky dirk brockstedt david j hinrichs darren e higgins jeffrey f miller martin giedlin h g archie bouwerj immunol  julveterans affairs medical center earle a chiles research institute department of molecular microbiology and immunology oregon health sciences university portland or  usajuly  download full paper an alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent genebased vaccine delivery vector authors silvia perri catherine e greer kent thudium barbara doe harold legg hong liu raul e romero zequn tang qian bin thomas w dubensky michael vajdy gillis r otten john m poloj virol  octvaccine research chiron corporation emeryville california  usa october  download full paper vesicular stomatitis virus an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from fields virology authors martin a giedlin david n cook thomas w dubenskycancer cell  octcancer research cerus corporation  stanwell drive concord ca  usaoctober  download full paper alphavirusbased dna vaccine breaks immunological tolerance by activating innate antiviral pathways authors wolfgang w leitner leroy n hwang michael j deveer aimin zhou robert h silverman bryan r g williams thomas w dubensky han ying nicholas p restifonat med  jan  epub  dec national cancer institute national institutes of health bethesda maryland usa january  download full paper generation of retroviral packaging and producer cell lines for largescale vector production with improved safety and titer authors thomas w dubensky sybille l sautermethods mol med  cerus corporation concord ca usajanuary  download full paper a highly efficient gene delivery system derived from feline immunodeficiency virus fiv authors sybille l sauter mehdi gasmi thomas w dubenskymethods mol med  genstar therapeutics inc san diego ca usajanuary  download full paper virusbased vectors for human vaccine applications authors john m polo thomas w dubenskydrug discov today  julchiron corporation immunology and infectious diseases  horton st emeryville ca  usa july  download full paper reengineering tumor cellselective replicating adenoviruses a step in the right direction toward systemic therapy for metastatic disease authors thomas w dubenskycancer cell  maycancer research cerus corporation  stanwell dr concord ca  usa may  download full paper of